Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5854231-A | Pharmaceutical composition for inhibiting the growth of cancers | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-29 | — | — | US | claimed |
| US-20220281967-A1 | NOVEL IL-17B ANTIBODIES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-09-08 | — | — | US | disclosed |
| US-20220175815-A1 | COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-06-09 | — | — | US | disclosed |
| US-20190240185-A1 | TREATMENT WITH ANTI ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10280228-B2 | Treatment with anti-ErbB2 antibodies | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190071516-A1 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190055317-A1 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-10160811-B2 | Treatment with anti-ErbB2 antibodies | GENENTECH, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| EP-2569335-B1 | METHODS OF TREATING AND/OR PREVENTING CELL PROLIFERATION DISORDERS WITH IL-17 ANTAGONISTS | OREGA BIOTECH (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-20170233468-A1 | IL-17 ANTAGONIST ANTIBODIES | OREGA BIOTECH (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20030162695-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2003-08-28 | — | — | US | disclosed |
| EP-1331005-A1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | Eisai Co., Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-6599943-B1 | Preventive treatment, related to the radical generating nature of the xanthine dehydrogenase/xanthine oxidase | WAPHARM AB (SE) | 2003-07-29 | — | — | US | disclosed |
| US-20030114379-A1 | Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) | HUMAN GENOME SCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| EP-0993304-B1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N GENE RES LAB INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2003-03-13 | — | — | US | disclosed |
| US-6495129-B1 | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) | HUMAN GENOME SCIENCES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | disclosed |
| EP-1007025-A1 | USE OF HYDROXYGUANIDINES | Wa Pharm AB (SE) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998023267-A1 | USE OF HYDROXYGUANIDINES | WAPHARM AB (SE) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDGF, CA7 | TOP2A 333/4885MEN1 403/4885KMT2A 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.